HOLKIRA PAK is now listed in the drug formularies covered by Quebec's public prescription drug insurance program for patients with genotype 1 hepatitis C virus infection. In Phase 3 clinical trials, HOLKIRA PAK (with or without ribavirin) cured an overall 97% of the genotype 1 hepatitis C virus patients; additionally, 98% of the patients completed the treatment. MONTREAL, July 24, 2015 /CNW/ - AbbVie, a global biopharmaceutical company, today announced that its treatment against hepatitis C, HOLKIRA PAK, is now listed in the drug formularies covered by Quebec's public prescription drug insurance plan (RPAMQ)1. HOLKIRA PAK (ombitasvir/paritaprevir/ ritonavir film-coated tablets; dasabuvir...
↧